MedTrace Logo

Everolimus Versus Placebo in Head and Neck Cancer

NCT01111058 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2020-04-07

Study results available
· View outcomes & findings →

Summary

Primary: Two-year progression-free (tumor does not grow or spread) survival in subjects treated with everolimus versus placebo after definitive local therapy.

Conditions

Interventions

DRUG

Everolimus (RAD 001)

10mg of Everolimus or Placebo taken by mouth once daily for 1 year or until progression (whichever comes first).

OTHER

Placebo

Sponsors & Collaborators

Principal Investigators

  • Tanguy Seiwert, M.D. · The University of Chicago Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2018-04-30
Completion
2018-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01111058 on ClinicalTrials.gov